The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Open accessAbstract
Prostate cancer remains a leading cause of cancer death, as there are no durable means to treat advanced disease. Treatment of non-organ confined prostate cancer hinges on its androgen dependence. First line therapeutic strategies suppress androgen receptor (AR) activity, via androgen ablation and direct AR antagonists. While initially effective, incurable, "castration-resistant" tumors arise due to resurgent AR activity. Alterations of AR and/or associated regulatory networks are known to restore receptor activity and support resultant therapy-resistant tumor progression. However, recent evidence also reveals an unexpected contribution of AR ligand, wherein alterations in pathways controlling androgen synthesis support castrate-resistant AR activity. Herein, mechanisms underlying the lethal pairing of AR deregulation and aberrant androgen synthesis in prostate cancer progression will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Cited by
Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D
Krishnan, A. V., & Feldman, D. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100611 · Cited by 470
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Self-citationHsieh, C.-L., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., Sun, T., Sweeney, C. J., Lee, G.-S. M., Chen, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324151111 · Cited by 398
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Liver X receptor biology and pharmacology: new pathways, challenges and opportunities
Jakobsson, T., Treuter, E., Gustafsson, J.-Å., & Steffensen, K. R. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.013 · Cited by 302
Epigenetics meets endocrinology
Zhang, X., & Ho, S.-M. (2011) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0053 · Cited by 298
Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1107 · Cited by 289
Regulation of FoxO transcription factors by acetylation and protein–protein interactions
Daitoku, H., Sakamaki, J.-I., & Fukamizu, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.001 · Cited by 283
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 256
Pretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159867 · Cited by 148
“Mechanisms proposed to be responsible for the continued AR activation include up-regulation of AR expression and/or gain-of-function mutations of the AR[6].”
BackgroundA new dawn for androgens: novel lessons from 11-oxygenated C19 steroids
Pretorius, E., Arlt, W., & Storbeck, K.-H. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.08.014 · Cited by 142
AKR1C3 as a target in castrate resistant prostate cancer
Adeniji, A. O., Chen, M., & Penning, T. M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.012 · Cited by 143
Self-citationUSP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
Self-citationSteroid sulfatase inhibitors for estrogen- and androgen-dependent cancers
Purohit, A., & Foster, P. A. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0266 · Cited by 126
“…breast, prostate, and endometrial, initially rely on steroid production for growth: only later in development do they usually become steroid-independent with the exception of prostate cancer which can remain androgen dependent even at late-stage (Knudsen & Penning 2010, de Bono et al. 2011).”
Byrns, M. C., Mindnich, R., Duan, L., & Penning, T. M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.12.012 · Cited by 60
Self-citationThe 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Metadata
- Authors
- Knudsen, K. E., & Penning, T. M.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 21
- Issue
- 5
- Pages
- 315-324
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2017896209
- Cited by
- 293
- References
- 95
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.